The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis. Intervention included food delivery svc & probiotic shot Limitations included study design issues such small sample size #ACR23 @RheumNow @rheumarhyme https://t.co/J6LEb0yONS

Don’t forget: 👉anti-HMGCR Ab in patients with immune mediated necrotizing myositis (may be assc with statins) 👉Anti-synthetase Ab assc with ILD, anti-synthetase syndrome #Rheum #BoardQuestion https://t.co/pBAADeR9ON

Persistence of IL-17i vs. TNFi in PsA treatment Large database study Persistence of IL-17i slightly greater than TNFi over 12 months Are IL-17i a better longterm strategy for PsA pts? @RheumNow #ACR23 Abs# 2240 https://t.co/9km5XgXcLE

#VEXAS is still hot at #ACR23 - 245K whole genome sequencing data from #NIH All of US - 74 with somatic mutation UBA1 Increased asthma, Tietze’s syndrome and neutropenia Hemoglobin similar in cases and controls @rheumnow #abstL03 https://t.co/A374w60e6H

Review of the limitations and possible toxicities with CAR-T treatment. ICANs and CRS, while treatable, are very important to educate and understand. This is part of the intersection of heme/onc and rheum. https://t.co/itbwLdHuqf

RheumNow’s expanded coverage of the #ACR23 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Rector et al. Pregnancy outcomes in vasculitis. More spontaneous abortion, elective termination, ectopic & molar pregnancy, x2 preterm delivery. Preeclampsia in 12%. Worse again in small vessel vasculitis Abstr#2425 #ACR23 @RheumNow https://t.co/cotncE16ma https://t.co/QoJpJIHJfJ

#ACRBest https://t.co/nx3bzhmeBW

There is a dose, duration and recency-dependent relationship between previous GC use and MACE. GC doses 5mg/day, durations of 30 days, and use one year prior to MACE were all associated with an increased risk of MACE, Wallace B Abst#2430 #ACR23 #ACRBest https://t.co/2ExboBvo2W https://t.co/FuqXdFFwqP

What % of pts in #RCTs in #SLE go in to #LLDAS - Pooling 5 RCTs - starting on #belimumab vs #placebo? More w #bDMARD @RheumNow @ACRheum #ACR23 abst#2551. True w DORIS - #lupus #rem but overall lower rates in each group https://t.co/VPZrYCVjof

The perks of a conference in San Diego The midday break with a view 🌞 🛥️ @RheumNow #ACR23 https://t.co/IRh7IRpWJz

A#2545 IV SEC for SpA #ACR23 @Rheumow Approved by FDA, though diff dose Who: Medicare/cost/QoL benefit for IV or obese (wt based dose) W16: 41% ASAS40 v 23% PBO W16, PBO switched to SEC. Efficacy W52 (SEC 67%, PBO/Sec 75%) SAE 6%, discontinuation 3.5% #ACRBest https://t.co/ruW0ys49gk

Development of New classification crieteria to target patients earlier in thier #OA disease course! One tatget molecule will not solve this heterogeneous disease! @rheumnow #ACR23 https://t.co/waynA6RdUg

Intriguing data on #GCA treated with tocilizumab #aneurysm still occurs #vasculitis https://t.co/6cPlFRReLJ

• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1
• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1
• https://twitter.com/MdWarrington/status/1724583931604058194/photo/1

A#2546 Anti-IFX Ab in AS #ACR23 @RheumNow Anti-IFX in 45% in f/u, 85% in 1st yr MTX decr anti-IFX (18 v 42%) Anti-IFX - higher inflamm markers, infus rxn, lower serum levels and Rx fail Pt w/o anti-IFX Ab more likely to tolerate tapering https://t.co/eN9SqGyGgm